Home Tags Daiichi Sankyo

Tag: Daiichi Sankyo

Global Phase II Study of DS-8201 in Patients with HER2-Expressing Advanced...

Following initiation of pivotal phase II studies in HER2-positive breast cancer and gastric cancer, the initiation of a third phase II study in colorectal...

Phase I Study of DS-1062 in Patients with Advanced Non-Small Cell...

The first patient has been dosed in a phase I study assessing the safety and tolerability of DS-1062, an investigational trophoblast cell-surface antigen 2...

Clinical Trial with Investigational Potential First-in-class HER3-targeting Antibody-drug Conjugate

A first patient has been dosed in a phase I study evaluating the safety and tolerability of U3-1402, in patients with metastatic or unresectable...

Ongoing Phase I Trial of DS-8201 Demonstrates Confirmed Increased Overall Response...

Updated analysis from ongoing phase I study of DS-8201 (trastuzumab deruxtecan), an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, demonstrated...

New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors Warrants Further...

In clinical trials, trastuzumab deruxtecan or DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, demonstrated preliminary antitumor activity in...

Breakthrough Therapy Designation for DS-8201 Confirms the Potential to Offer Substantial...

The U.S. Food and Drug Administration (FDA) earlier today confirmed that it has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody-drug conjugate...

Nivolumab and DS-8201 to be Evaluated in HER2-Expressing Breast and Bladder...

Bristol-Myers Squibb and Daiichi Sankyo have agreed to collaborate in a clinical trial to evaluate the combination of Bristol-Myers Squibb’s immunotherapy nivolumab (Opdivo®) and...

Daiichi Sankyo Invests in the Future of Antibody-drug Conjugates

Daiichi Sankyo is making an initial Japanese ¥ 15 billion (US $ 135 million) investment to optimize and enhance its manufacturing capabilities to support...

X